Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: application of the Global Burden of Disease framework

Katrin Burkart(University of Washington), Elizabeth Begier(Pfizer (United States)), Marion Fahey(Pfizer (Ireland)), Catherine W. Gillespie(University of Washington), Mariana Haeberer(Pfizer (Spain)), Susan McLaughlin(University of Washington), Caihua Liang(Pfizer (United States)), Ana Gabriela Grajales(Pfizer (Canada)), Bradford D. Gessner(Pfizer (United States)), Quinn Rafferty(Institute for Health Metrics and Evaluation), Asuka Yoshida(Hiroshima University), Andrei Oros(Institute for Health Metrics and Evaluation), Caroline Lade(Pfizer (Germany)), Jam Suba(University of Washington)
EClinicalMedicine
June 16, 2025
10.1016/j.eclinm.2025.103292
Cited by 13

Related Papers

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.1k
The Global Burden of Cancer 2013
|JAMA Oncology|2015|2.8k
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
|The Lancet|2017|2.4k
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021
|The Lancet Rheumatology|2023|1.7k
Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis
|The Lancet|2011|999